Exelixis (EXEL) : Simplex Trading added new position in Exelixis during the most recent quarter end. The investment management firm now holds 30,210 shares of Exelixis which is valued at $391,220 , the company said in a statement filed on Oct 7, 2016 with the SEC.Exelixis makes up approximately 0.05% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa boosted its stake in EXEL in the latest quarter, The investment management firm added 81,751 additional shares and now holds a total of 90,581 shares of Exelixis which is valued at $1,188,423.
Exelixis closed down -0.23 points or -1.75% at $12.95 with 81,07,094 shares getting traded on Friday. Post opening the session at $13.33, the shares hit an intraday low of $12.33 and an intraday high of $13.3389 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Exelixis reported $-0.16 EPS for the quarter, beating the analyst consensus estimate by $ 0.11 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.27. The company had revenue of $36.25 million for the quarter, compared to analysts expectations of $16.37 million. The company’s revenue was up 353.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.22 EPS.
Many Wall Street Analysts have commented on Exelixis. Exelixis was Upgraded by Piper Jaffray to ” Overweight” on Oct 10, 2016. Company shares were Reiterated by Stifel on Sep 15, 2016 to “Buy”, Firm has raised the Price Target to $ 15 from a previous price target of $12 .Company shares were Reiterated by Stifel on Aug 4, 2016 to “Buy”, Firm has raised the Price Target to $ 12 from a previous price target of $10 .
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive metastatic medullary thyroid cancer (MTC) in the United States. The Company’s other programs include metastatic renal cell carcinoma (mRCC) a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888 a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).